{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:19:10Z","timestamp":1789510750749,"version":"build-2803163510"},"reference-count":145,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009011","name":"Heze University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016694","name":"Science and Technology Development Plan of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as the predominant chronic liver condition globally. Although pharmacological options have recently emerged for selected patients with MASH and moderate-to-advanced fibrosis, pharmacological treatment remains limited. Recent studies have provided compelling evidence demonstrating that both the gut microbiota and bile acids (BAs) undergo remarkable alterations in NAFLD and contribute substantially to disease progression. The farnesoid X receptor (FXR), a crucial nuclear receptor, plays a central role in the synthesis and metabolism of BAs and also regulates glucose and lipid metabolism while attenuating inflammatory responses. Because of these diverse functions, FXR has become a key focus as a potential therapeutic target for NAFLD. This review provides a comprehensive summary of the interactions between the gut microbiota and BAs, detailing their specific metabolic alterations in NAFLD. It also explains the molecular mechanisms through which FXR regulates glucose and lipid metabolism and offers an up-to-date overview of emerging therapeutic strategies that target the gut microbiota\u2013BA\u2013FXR axis for NAFLD. This review integrates current evidence to clarify how the gut microbiota\u2013BA\u2013FXR axis contributes to NAFLD\/MASLD pathogenesis and therapeutic development, which are expected to offer new insights for filling the current unmet clinical need in NAFLD treatment.<\/jats:p>","DOI":"10.3389\/fphys.2026.1811118","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:49:21Z","timestamp":1783486161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The gut microbiota-bile acid-FXR axis in NAFLD: from progression to therapeutic applications"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Zheng","sequence":"first","affiliation":[{"name":"College of Pharmacy, Heze University","place":["Heze, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Feng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University","place":["Heze, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University","place":["Heze, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpeng","family":"Li","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University","place":["Heze, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yin","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University","place":["Heze, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40495-017-0085-2","article-title":"Role of FXR in liver inflammation during nonalcoholic steatohepatitis","volume":"3","author":"Armstrong","year":"2017","journal-title":"Curr. Pharmacol. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156680","article-title":"Stevia rebaudiana root polysaccharide modulates liver metabolism, bile acid, and gut microbiota improving HFD-induced NAFLD: Potential roles of ACSL1 and FADS2","volume":"141","author":"Bao","year":"2025","journal-title":"Phytomedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s43066-024-00378-9","article-title":"Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease","volume":"14","author":"Basuni","year":"2024","journal-title":"Egyptian Liver J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.26225","article-title":"Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis","volume":"57","author":"Bechmann","year":"2013","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1152\/ajpendo.00409.2016","article-title":"Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption","volume":"313","author":"Bertaggia","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/livers6030045","article-title":"Experimental rodent models of metabolic dysfunction-associated fatty liver disease: present status and future perspective","author":"Bhopale","year":"2026"},{"key":"B9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2337\/dbi17-0007","article-title":"Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery","volume":"67","author":"Bozadjieva","year":"2018","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13679-019-00334-4","article-title":"Changes in bile acid metabolism, transport, and signaling as central drivers for metabolic improvements after bariatric surgery","volume":"8","author":"Browning","year":"2019","journal-title":"Curr. Obes. Rep."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41575-022-00631-9","article-title":"Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms","volume":"19","author":"Cani","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.858795","article-title":"Multi-omics integration analysis identifies lipid disorder of a non-alcoholic fatty liver disease (NAFLD) mouse model improved by Zexie-Baizhu decoction","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70229","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of INT-787, a novel farnesoid X receptor agonist, in healthy volunteers: a phase 1 trial","volume":"18","author":"Capozza","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/ijms23158805","article-title":"The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"23","author":"Carpi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1343755","article-title":"Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01979-23","article-title":"Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota","volume":"12","author":"Chen","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/toxsci\/kfn161","article-title":"Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers","volume":"106","author":"Cheng","year":"2008","journal-title":"Toxicol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1096\/fj.201701084RR","article-title":"Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice","volume":"32","author":"Chevre","year":"2018","journal-title":"FASEB J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile acid metabolism in liver pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-nutr-082018-124344","article-title":"Bile acids as metabolic regulators and nutrient sensors","volume":"39","author":"Chiang","year":"2019","journal-title":"Annu. Rev. Nutr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/0005-2736(80)90075-9","article-title":"Membrane lipid composition and susceptibility to bile salt damage","volume":"599","author":"Coleman","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"B28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120269","article-title":"Huaganjian decoction ameliorates metabolic dysfunction-associated steatotic liver disease through liver-gut crosstalk","volume":"353","author":"Dong","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29971","DOI":"10.1074\/jbc.M501931200","article-title":"The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition","volume":"280","author":"Duran-Sandoval","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2024.106589","article-title":"Free fatty acids induce bile acids overproduction and oxidative damage of bovine hepatocytes via inhibiting FXR\/SHP signaling","volume":"244","author":"Fang","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molmed.2021.10.005","article-title":"Linking liver metabolic and vascular disease via bile acid signaling","volume":"28","author":"Fiorucci","year":"2022","journal-title":"Trends Mol. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.tips.2009.08.001","article-title":"Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders","volume":"30","author":"Fiorucci","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/ph18091424","article-title":"Obeticholic acid and other farnesoid-X-receptor (FXR) agonists in the treatment of liver disorders","volume":"18","author":"Fiorucci","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal. Transduct Target Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1053\/j.gastro.2023.02.022","article-title":"The gut microbial bile acid modulation and its relevance to digestive health and diseases","volume":"164","author":"Fogelson","year":"2023","journal-title":"Gastroenterology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J. Hepatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1046\/j.1472-765x.1997.00180.x","article-title":"Influence of various bile salts on beta-glucuronidase activity of intestinal bacteria","volume":"25","author":"Fujisawa","year":"1997","journal-title":"Lett. Appl. Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens3010014","article-title":"Metabolism of cholesterol and bile acids by the gut microbiota","volume":"3","author":"G\u00e9rard","year":"2013","journal-title":"Pathogens"},{"key":"B44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/joim.12594","article-title":"Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III","volume":"281","author":"Ghosh Laskar","year":"2017","journal-title":"J. Intern. Med."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100387","article-title":"Bile acids contribute to the development of non-alcoholic steatohepatitis in mice","volume":"4","author":"Gillard","year":"2022","journal-title":"JHEP Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","article-title":"Human gut microbiota\/microbiome in health and diseases: a review","volume":"113","author":"Gomaa","year":"2020","journal-title":"Antonie van Leeuwenhoek"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/cells8111358","article-title":"Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression","volume":"8","author":"Gottlieb","year":"2019","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s42003-024-07158-6","article-title":"Cross-comparison of gut metagenomic profiling strategies","volume":"7","author":"Guly\u00e1s","year":"2024","journal-title":"Commun. Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1039\/d0fo00436g","article-title":"Ganoderic acid A from Ganoderma lucidum ameliorates lipid metabolism and alters gut microbiota composition in hyperlipidemic mice fed a high-fat diet","volume":"11","author":"Guo","year":"2020","journal-title":"Food Funct."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1645298","DOI":"10.3389\/fmicb.2025.1645298","article-title":"Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance","author":"Guo","year":"2025"},{"key":"B51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.ircmb.2024.12.008","article-title":"Effect of diet and lifestyle on microbiome composition","volume":"395","author":"Gupta","year":"2025","journal-title":"Int. Rev. Cell. Mol. Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","article-title":"Review: microbial transformations of human bile acids","volume":"9","author":"Guzior","year":"2021","journal-title":"Microbiome"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human insulin resistance is associated with increased plasma levels of 12\u03b1-hydroxylated bile acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"key":"B54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/s0022-2275(20)37599-4","article-title":"Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection","volume":"37","author":"Heuman","year":"1996","journal-title":"J. Lipid Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2147\/dddt.S170518","article-title":"Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis","volume":"12","author":"Hu","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1038\/s41467-019-12896-x","article-title":"Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12938\/bmfh.2020-046","article-title":"Correlation of gut Firmicutes\/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease","volume":"40","author":"Jasirwan","year":"2021","journal-title":"Biosci. Microbiota Food. Health"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/nu11081712","article-title":"Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD)","volume":"11","author":"Ji","year":"2019","journal-title":"Nutrients"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2025.e00508","article-title":"Towards the clinical use of peripheral bile acids: Recommendations to limit their preanalytical and analytical sources of variability","volume":"47","author":"Joseph","year":"2025","journal-title":"Pract. Lab. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/liv.15030","article-title":"Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus","volume":"41","author":"Jung","year":"2021","journal-title":"Liver Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13568-025-01921-6","article-title":"Demographic drivers of gut microbiome diversity","volume":"15","author":"Kabir","year":"2025","journal-title":"AMB Express"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.3390\/ijms23116046","article-title":"Molecular basis of bile acid-FXR-FGF15\/19 signaling axis","volume":"23","author":"Katafuchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/ijerph22101591","article-title":"Meta-analysis of the gut microbiome: An African American representation","volume":"22","author":"Kc","year":"2025","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1038\/s41467-020-19803-9","article-title":"Intestinal FGF15\/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118332","article-title":"FXR-targeted drug discovery: Recent advances and therapeutic perspectives","volume":"302","author":"Li","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1447878","article-title":"Regulation of bile acids and their receptor FXR in metabolic diseases","volume":"11","author":"Li","year":"2024","journal-title":"Front. Nutr."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/hep.30975","article-title":"Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41564-023-01570-0","article-title":"Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids","volume":"9","author":"Liu","year":"2024","journal-title":"Nat. Microbiol."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120217","article-title":"Clinical application of bile acid profile combined with lipid indices in metabolic dysfunction-associated steatotic liver disease","volume":"570","author":"Liu","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmicr.2024.100315","article-title":"Gut microbiota and bile acids: Metabolic interactions and impacts on diabetic kidney disease","volume":"7","author":"Liu","year":"2024","journal-title":"Curr. Res. Microb. Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/jgh.16279","article-title":"Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis","volume":"38","author":"Liu","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110024","article-title":"Role of FXR in the development of NAFLD and intervention strategies of small molecules","volume":"757","author":"Long","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"key":"B78","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12906-023-04009-5","article-title":"Tianhuang formula regulates adipocyte mitochondrial function by AMPK\/MICU1 pathway in HFD\/STZ-induced T2DM mice","volume":"23","author":"Luo","year":"2023","journal-title":"BMC Complement Med. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"fuad039","DOI":"10.1093\/femsre\/fuad039","article-title":"Faecalibacterium: a bacterial genus with promising human health applications","volume":"47","author":"Mart\u00edn","year":"2023","journal-title":"FEMS Microbiol. Rev."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e0377","DOI":"10.1097\/hc9.0000000000000377","article-title":"Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD","volume":"8","author":"Murphy","year":"2024","journal-title":"Hepatol. Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J. Hepatol."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer","year":"2021","journal-title":"Metabolism"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1038\/s41598-018-23296-4","article-title":"Methodology challenges in studying human gut microbiota \u2013 effects of collection, storage, DNA extraction and next generation sequencing technologies","volume":"8","author":"Panek","year":"2018","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41522-024-00566-w","article-title":"Effects of bile acids on the growth, composition and metabolism of gut bacteria","volume":"10","author":"Peng","year":"2024","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B87","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1146\/annurev-physiol-031522-092054","article-title":"The role of the gut microbiota in the relationship between diet and human health","volume":"85","author":"Perler","year":"2023","journal-title":"Annu. Rev. Physiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: Pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11684-018-0644-x","article-title":"Bile acids and their effects on diabetes","volume":"12","author":"Rajani","year":"2018","journal-title":"Front. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/19490976.2019.1618173","article-title":"The 'in vivo lifestyle' of bile acid 7\u03b1-dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice","volume":"11","author":"Ridlon","year":"2020","journal-title":"Gut Microbes"},{"key":"B96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"B97","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J. Lipid Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41586-023-06990-w","article-title":"Bile salt hydrolase catalyses formation of amine-conjugated bile acids","volume":"626","author":"Rimal","year":"2024","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann. Hepatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic BA derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/19490976.2016.1256525","article-title":"Nutrition and the gut microbiome in the elderly","volume":"8","author":"Salazar","year":"2017","journal-title":"Gut Microbes"},{"key":"B103","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.csbj.2023.11.047","article-title":"Combined analysis of cross-population healthy adult human microbiome reveals consistent differences in gut microbial characteristics between Western and non-Western countries","volume":"23","author":"Sheng","year":"2024","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118700","article-title":"Zexie-Baizhu Decoction ameliorates non-alcoholic fatty liver disease through gut-adipose tissue crosstalk","volume":"337","author":"Shi","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118203","article-title":"Discovery of novel potent indazole-based FXR agonists via scaffold hopping for MASH treatment","volume":"301","author":"Shi","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"Smirnova","year":"2022","journal-title":"Hepatology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.3390\/nu16183134","article-title":"The effect of dietary types on gut microbiota composition and development of non-communicable diseases: a narrative review","volume":"16","author":"Sold\u00e1n","year":"2024","journal-title":"Nutrients"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-019-0628-3","article-title":"Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome","volume":"7","author":"Song","year":"2019","journal-title":"Microbiome"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3727\/105221617x15093707969658","article-title":"Updates on dietary models of nonalcoholic fatty liver disease: current studies and insights","volume":"18","author":"Stephenson","year":"2018","journal-title":"Gene Expr"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1907272","article-title":"Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease","volume":"13","author":"Stoeva","year":"2021","journal-title":"Gut Microbes"},{"key":"B113","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J. Lipid Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B116","year":"2021","journal-title":"Terns Reports Positive Top\u2011line Results from Phase 2a LIFT Study of FXR Agonist TERN\u2011101 in Patients with NASH"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","article-title":"FXR: structures, biology, and drug development for NASH and fibrosis diseases","volume":"43","author":"Tian","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"B118","doi-asserted-by":"publisher","first-page":"7629","DOI":"10.1038\/ncomms8629","article-title":"Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells","volume":"6","author":"Trabelsi","year":"2015","journal-title":"Nat. Commun."},{"key":"B119","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"B120","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/164_2019_233","article-title":"Potential of intestine-selective FXR modulation for treatment of metabolic disease","volume":"256","author":"van Zutphen","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157404","article-title":"Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis","volume":"148","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102530","article-title":"The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice","volume":"298","author":"Wang","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jare.2025.05.014","article-title":"Hyperoside modulates bile acid and fatty acid metabolism, presenting a potentially promising treatment for non-alcoholic fatty liver disease","volume":"80","author":"Wang","year":"2026","journal-title":"J Adv Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/jci21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194252","article-title":"CCAAT-enhancer binding protein-\u03b1 (C\/EBP\u03b1) and hepatocyte nuclear factor 4\u03b1 (HNF4\u03b1) regulate expression of the human fructose-1,6-bisphosphatase 1 (FBP1) gene in human hepatocellular carcinoma HepG2 cells","volume":"13","author":"Wattanavanitchakorn","year":"2018","journal-title":"PloS One"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1341938","article-title":"Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions","volume":"15","author":"Wei","year":"2024","journal-title":"Front. Microbiol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e142865","DOI":"10.1172\/jci142865","article-title":"Suppressing the intestinal farnesoid X receptor\/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis","volume":"131","author":"Wu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B129","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s13238-020-00814-7","article-title":"The role of the gut microbiome and its metabolites in metabolic diseases","volume":"12","author":"Wu","year":"2021","journal-title":"Protein Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2302065","article-title":"Prophylactic treatment with Bacteroides uniformis and Bifidobacterium bifidum counteracts hepatic NK cell immune tolerance in nonalcoholic steatohepatitis induced by high fat diet","volume":"16","author":"Xu","year":"2024","journal-title":"Gut Microbes"},{"key":"B131","doi-asserted-by":"publisher","first-page":"23158","DOI":"10.1074\/jbc.M314322200","article-title":"Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1","volume":"279","author":"Yamagata","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B132","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.1038\/s41467-022-34258-w","article-title":"Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism","volume":"13","author":"Yan","year":"2022","journal-title":"Nat. Commun."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.clnu.2024.04.004","article-title":"Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"43","author":"Yang","year":"2024","journal-title":"Clin. Nutr."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119801","article-title":"Schisandra chinensis lignans ameliorate hepatic inflammation and steatosis in methionine choline-deficient diet-fed mice by modulating the gut-liver axis","volume":"348","author":"Yan","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"759","DOI":"10.21037\/hbsn-23-342","article-title":"Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved","volume":"12","author":"Yoneda","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.698852","article-title":"Disease-associated gut microbiota reduces the profile of secondary bile acids in pediatric nonalcoholic fatty liver disease","volume":"11","author":"Yu","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154444","article-title":"Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling","volume":"107","author":"Zhai","year":"2022","journal-title":"Phytomedicine"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1333778","article-title":"Gut microbiota and therapy for obesity and type 2 diabetes","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B141","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4239\/wjd.v15.i3.392","article-title":"Roles of fibroblast growth factors in the treatment of diabetes","volume":"15","author":"Zhang","year":"2024","journal-title":"World J. Diabetes"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00802","article-title":"Unraveling the regulation of hepatic gluconeogenesis","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B143","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1007\/s00253-020-10633-9","article-title":"Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation","volume":"104","author":"Zhao","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.placenta.2021.07.286","article-title":"FGF15\/FGF19 alleviates insulin resistance and upregulates placental IRS1\/GLUT expression in pregnant mice fed a high-fat diet","volume":"112","author":"Zhao","year":"2021","journal-title":"Placenta"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.243","article-title":"Novel microbial modifications of bile acids and their functional implications","volume":"3","author":"Zheng","year":"2024","journal-title":"Imeta"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2026.1811118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:49:36Z","timestamp":1783486176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2026.1811118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":145,"alternative-id":["10.3389\/fphys.2026.1811118"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2026.1811118","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1811118"}}